Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effects of Inhaled Nitric Oxide on Patient Morbidity and Length of Hospital Stay Following Fontan Operation

Next Previous
Trial Profile

The Effects of Inhaled Nitric Oxide on Patient Morbidity and Length of Hospital Stay Following Fontan Operation

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 22 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Pleural effusion
  • Focus Therapeutic Use

Most Recent Events

  • 26 Apr 2023 Time frame of primary endpoint has been changed from 2 weeks to until hospital discharge.
  • 03 May 2012 Actual patient number added 21 according to ClinicalTrials.gov.
  • 03 May 2012 Actual end date (December 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top